1. |
|
|
2. |
- Ren, Tie-Zhen, et al.
(författare)
-
Single crystal manganese oxide hexagonal plates with regulated mesoporous structures
- 2008
-
Ingår i: Microporous and Mesoporous Materials. - : Elsevier BV. - 1387-1811 .- 1873-3093. ; 112:03-jan, s. 467-473
-
Tidskriftsartikel (refereegranskat)abstract
- Porous hexagonal plates of manganese oxides are prepared by a simple hydrothermal method from metal Mn foils/powders and manganese acetate precursors tinder basic conditions. The oriented aggregation-based assembly of the nanoparticles of mixed feitknechtite and hausmannite phases gave rise to well-defined hexagonal nanoplates with irregular mesopores of similar to 5 nm in size. The hexagonal plate-like morphology was retained after calcination, and mesoporous single-crystalline Mn5O8 and alpha-Mn2O3 plates were obtained after calcinations at 400 and 700 degrees C, respectively. The interior mesopores in each plate were enlarged with the increase of calcination temperature, and turned out to be regular-shaped, i.e. polyhedral or even well-defined rectangular. Furthermore, 700 degrees C-calcination led to the fusion of nanocrystals into structurally uniform alpha-Mn2O3 crystals of hexagonal plates with regular-shaped mesoporous structure. X-ray diffraction and electron diffraction, scanning and transmission electron microscopy, X-ray energy dispersive spectroscopy, and nitrogen sorption analysis were employed to characterize these porous nanoplates. Such mesoporous hexagonal nanoplates of manganese oxides with high crystallinity may have many applications.
|
|
3. |
|
|
4. |
- Wang, Ming-Wei, et al.
(författare)
-
FXYD3 Expression in Gliomas and its Clinicopathological Significance
- 2009
-
Ingår i: Oncology Research. - : Computers, Materials and Continua (Tech Science Press). - 0965-0407 .- 1555-3906. ; 18:4, s. 133-139
-
Tidskriftsartikel (refereegranskat)abstract
- FXYD3, interacting with Na+/K+-ATPase, is considered a cell surface regulator modulating the function of ion pumps and ion channels. The FXYD3 gene was originally cloned from murine mammary tumors and then from human breast tumors. However, no study of FXYD3 has been carried out in gliomas; therefore, we examined FXYD3 expression in gliomas and its clinicopathological significance. FXYD3 expression was immunohistochemically examined in 71 primary gliomas, along with 37 matched adjacent normal brain samples and 8 recurred gliomas. The frequency of strong FXYD3 expression was higher in the primary tumors in either unmatched (p = 0.046) or matched cases (p = 0.02), compared to normal brain tissue. FXYD3 expression was significantly more increased in females than males (p = 0.01), and in multiple site gliomas than single sites (p = 0.02). There was no difference of FXYD3 expression regarding age, tumor location, size, histological type, and tumor grade (p greater than 0.05). The results suggest that FXYD3 expression may be involved in glioma development, especially in multiple gliomas and female patients.
|
|